Search alternatives:
point decrease » point increase (Expand Search)
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
481
Klf5 activates the transcription of the eIF5a gene through direct binding to its promoter.
Published 2020Subjects: -
482
Image 5_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif
Published 2024“…</p>Methods<p>Mice were inoculated with 10<sup>7</sup> CFU of the eubiotic bacteria Lactobacillus crispatus, the dysbiotic bacteria G. vaginalis, or PBS as a negative control every 48 h for ten days. On day ten, mice were inoculated with 10<sup>5</sup> PFU WT HSV-2 333 and survival, pathology, and viral titers were assessed. …”
-
483
Effects of conivaptan on brain water content (BWC), blood-brain-barrier (BBB) disruption, plasma and urine sodium and osmolality.
Published 2015“…Following MCAO, Evans Blue (EB) extravasation index (I/C) was increased in vehicle treated mice, and reduced in conivaptan treated mice, naïve, n = 5, vehicle, n = 8, Conivaptan 0.2 mg, n = 8. (C, D) Conivaptan treatment of 0.2 mg resulted in an elevation of plasma sodium and osmolality, and decreased urine sodium and osmolality due to aquaresis. …”
-
484
-
485
-
486
-
487
Image5_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg
Published 2024“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
-
488
-
489
-
490
-
491
-
492
XRD pattern of (a) virgin sample (b) 0.4 wt. % <i>f-MWCNTs</i> glass fiber composite.
Published 2022Subjects: -
493
-
494
-
495
-
496
-
497
-
498
-
499
-
500